Skip to main content
Top
Published in: BMC Gastroenterology 1/2023

Open Access 01-12-2023 | Portal Vein Thrombosis | Research article

Analysis of related factors of portal vein thrombosis in liver cirrhosis

Authors: Xiaotong Xu, Jinglan Jin, Yuwei Liu, Hang Li

Published in: BMC Gastroenterology | Issue 1/2023

Login to get access

Abstract

Background and aims

To investigate the usefulness of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), protein C (PC), and thromboelastography (TEG) to serve as a predictor of portal vein thrombosis (PVT) in patients with liver cirrhosis. Additionally, we examined the clinical significance of the above indicators in terms of disease progression.

Methods

A total of 123 patients with liver cirrhosis were recruited from May 2021 to December 2021, according to the imaging findings. They were divided into the PVT group (n = 52) and the non-PVT group (n = 71). Furthermore, patients with PVT were divided into plasma transfusion groups (n = 13) and non-plasma transfusion groups (n = 39). The basic general information, past medical history, laboratory, and imaging examination data were collected and analyzed.

Results

In univariate analysis, there was no significant difference between the two groups in IL-6, PC, reaction time (R), alpha angle (Angle), maximum amplitude, or coagulation index (CI) (P > 0.05). TNF-α in the PVT group was significantly lower than that in the non-PVT group (P = 0.001). K-time (K) in the PVT group was significantly higher than that in the non-PVT group (P = 0.031). There was no significant difference in IL-6, TNF-α, PC, or TEG between different Child–Pugh classification groups (P > 0.05). There were no significant differences in TEG between the plasma transfusion group and the non-plasma transfusion group. In Binary logistic regression analysis, TNF-α (OR = 0.9881, 95%CI = 0.971, 0.990, P < 0.001), K(OR = 1.28, 95% = 1.053, 1.569, P = 0.014), activate partial thromboplastin time (APTT) (OR = 0.753, 95%CI = 0.656, 0.865, P < 0.001), portal vein diameter (OR = 1.310, 95%CI = 1.108, 1.549, P = 0.002)and the history of splenectomy or embolism (OR = 7.565, 95%CI = 1.514, 37.799, P = 0.014)were related to the formation of PVT.

Conclusions

TNF-α, K, APTT, portal vein diameter, and splenectomy or embolism history were associated with PVT formation, but IL-6 was not.
Literature
9.
go back to reference Chinese Society of Hepatology Chinese Medical Association. Chines guidelines on the management of liver cirrohosis [J]. Journal of Clinical Hepatology, 2019, 35(11). Chinese Society of Hepatology Chinese Medical Association. Chines guidelines on the management of liver cirrohosis [J]. Journal of Clinical Hepatology, 2019, 35(11).
10.
go back to reference Hepatobiliary Disease Study Group Chinese Society of Gastroenterology Chinese Medical Association. Consensus for management of portal vein thrombosis in liver cirrhosis (2020, Shanghai) [J]. J Clin Hepatol, 2020, 36(12): 2667–2673. Hepatobiliary Disease Study Group Chinese Society of Gastroenterology Chinese Medical Association. Consensus for management of portal vein thrombosis in liver cirrhosis (2020, Shanghai) [J]. J Clin Hepatol, 2020, 36(12): 2667–2673.
24.
go back to reference Nosaka M, Ishida Y, Kimura A, et al. Contribution of the tnf-α (tumor necrosis factor-α)–tnf-rp55 (tumor necrosis factor receptor p55) axis in the resolution of venous thrombus [J]. Arterioscler Thromb Vasc Biol. 2018;38(11):2638–50.CrossRef Nosaka M, Ishida Y, Kimura A, et al. Contribution of the tnf-α (tumor necrosis factor-α)–tnf-rp55 (tumor necrosis factor receptor p55) axis in the resolution of venous thrombus [J]. Arterioscler Thromb Vasc Biol. 2018;38(11):2638–50.CrossRef
Metadata
Title
Analysis of related factors of portal vein thrombosis in liver cirrhosis
Authors
Xiaotong Xu
Jinglan Jin
Yuwei Liu
Hang Li
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2023
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-022-02632-z

Other articles of this Issue 1/2023

BMC Gastroenterology 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.